1-3 of 3
Zoulika Kherrouche
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 3683: MET exon 14 skipping mutations in lung cancer: Screening, functional and clinical impact

Marie Fernandes, Philippe Jamme, Sonia Paget, Angela Morabito, Frédéric Leprêtre, Martin Figeac, Clotilde Descarpentries, Fabienne Escande, Simon Baldacci, Anne Chotteau-Lelièvre, Luca Grumolato, Marie-Christine Copin, Zoulika Kherrouche, Alexis B. Cortot, David Tulasne
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 3683.
https://doi.org/10.1158/1538-7445.AM2020-3683
Published: 15 August 2020
View article titled, Abstract 3683: MET exon 14 skipping mutations in lung cancer: Screening, functional and clinical impact
Journal Articles

Thirty Years of Research on Met Receptor to Move a Biomarker from Bench to Bedside

Alessandro Furlan, Zoulika Kherrouche, Rémi Montagne, Marie-Christine Copin, David Tulasne
Journal: Cancer Research
Cancer Res (2014) 74 (23): 6737–6744.
https://doi.org/10.1158/0008-5472.CAN-14-1932
Published: 30 November 2014
View article titled, Thirty Years of Research on Met Receptor to Move a Biomarker from Bench to Bedside
Open the PDF for Thirty Years of Research on Met Receptor to Move a Biomarker from Bench to Bedside in another window
Journal Articles

Abstract 2559: Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma

Nicholas A. Saunders, Rafael Erlich, Zoulika Kherrouche, Mehlika Hazar-Rethinam, Lilia Merida de Long, Alexander Guminski
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 2559.
https://doi.org/10.1158/1538-7445.AM2011-2559
Published: 15 April 2011
View article titled, Abstract 2559: Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma